In vitro response to mitogens and antigens in elderly and post-cytotoxic patients can be modified by a new hypoxanthine derivative (PCF-39).
The in vitro immunomodulatory properties of the hypoxanthine derivative N alpha-5(1.6-dihidro-6-oxo-9-purinyl)pentyloxy/carbonyl -L-arginine (PCF-39) are described. Data obtained with PHA in vitro indicate that PCF-39 exhibits immunopharmacologic activity in elderly and post-cytotoxic patients, while showing no significant activity in normal donors. Antigen induced proliferation was unaffected by PCF-39, while PMN induced chemiluminescence was significantly enhanced. PCF-39 can be considered a new drug in the family of the hypoxanthine derivatives endowed with immunomdulatory properties.
Melino
G
G
Department of Biochemistry and Experimental Medicine, University of Rome, Italy.
Melodia
A
A
Perezzani
L
L
Bertelli
R
R
Knight
R A
RA
Cornaglia-Ferraris
P
P
D000368:Aged; D000375:Aging / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology*; D006801:Humans; D007042:Hypoxanthines / Q000494:pharmacology*; D007111:Immunity, Cellular / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects*; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology*; D010835:Phytohemagglutinins / Q000494:pharmacology
D000970:Antineoplastic Agents; D007042:Hypoxanthines; D010835:Phytohemagglutinins; C054420:PCF 39; D001120:Arginine